Corindus Vascular Robotics is to feature its CorPath GRX system at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego, USA). The system is the first FDA-cleared medical device for robotic-assisted vascular interventions. A press release reports that the company will showcase its revolutionary technology throughout the conference through live cases and presentations, during a Corindus-sponsored breakfast symposium, and at Booth 421.
On the Sunday of the meeting (23 September) from 6:30am— 8:00 am, Corindus’ Cardiovascular chief medical officer Aaron Grantham (St Luke’s Hospital, Kansas City, USA) will chair the breakfast symposium “New Frontiers in Robotic Interventions: Current and Future Technology”.
Aaron Grantham, comments: “I am pleased to chair this educational programme with an esteemed group of interventionalists to highlight the current and future capabilities of vascular robotics. There has been tremendous progress made in the development of our robotic platform, including procedural automation and remote technology, which we believe will have the power to change the treatment paradigm and increase patient access to care.”
The CorPath GRX System will be on display at Corindus’ Booth 421. The press release states that attendees will have the opportunity to be among the first to experience future procedural automation techniques and compete with their peers in a wiring challenge.
